141 related articles for article (PubMed ID: 1680450)
1. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity.
Bajo MA; Selgas R; Miranda B; Fernandez-Zamorano A; Borrego F; Romero JR; Caparros G; Riñon C; Sanchez Sicilia L
Adv Perit Dial; 1991; 7():296-300. PubMed ID: 1680450
[TBL] [Abstract][Full Text] [Related]
2. Treatment of the anemia with human recombinant erythropoietin in CAPD patients.
Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L
Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831
[TBL] [Abstract][Full Text] [Related]
3. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
Bunke M; Bartlett DK; Brier ME; Golper TA
Adv Perit Dial; 1993; 9():331-5. PubMed ID: 8105957
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.
Vega N; Fernandez A; Hortal L; Macias M; Rodriguez JC; Plaza C; Perdomo M; Vega R; Palop L
Adv Perit Dial; 1992; 8():467-70. PubMed ID: 1361850
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
Icardi A; Paoletti E; Molinelli G
Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant human erythropoietin in patients on CAPD.
Lye WC; Lee EJ
Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
[TBL] [Abstract][Full Text] [Related]
7. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
8. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
9. Experience with subcutaneous erythropoietin in CAPD patients.
Bailie GR; Plitnick R; Eisele G; Clement C; Rasmussen R
Adv Perit Dial; 1991; 7():292-5. PubMed ID: 1680449
[TBL] [Abstract][Full Text] [Related]
10. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
12. How does rHuEPO effect D/P creatinine ratios?
Richmond D; Broyan P; Shea S; Reft C; Poseno M; Gimenez LF
Adv Perit Dial; 1992; 8():457-9. PubMed ID: 1361847
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
Abreo K; Lubom JA; Collier L; Fleming D; Work J
Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
[TBL] [Abstract][Full Text] [Related]
14. Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
Pilkey RM; Morton AR; Iliescu EA
Adv Perit Dial; 2001; 17():153-7. PubMed ID: 11510266
[TBL] [Abstract][Full Text] [Related]
15. [Anemia in patients on continuous ambulatory peritoneal dialysis (CAPD)].
Tokuda Y; Itou H; Uchida Y; Azuma K; Ohtsuka H; Uomizu K; Yamashita W; Harada R; Nakashima A; Morita T
Fukuoka Igaku Zasshi; 1989 Jul; 80(7):379-84. PubMed ID: 2807127
[TBL] [Abstract][Full Text] [Related]
16. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
Saleh A; Krane NK; Caballero M; Starks E
Adv Perit Dial; 1991; 7():288-91. PubMed ID: 1680448
[TBL] [Abstract][Full Text] [Related]
17. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
19. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin (rHuEPO) therapy has no effect on peritoneal transport in CAPD patients: a short-term study.
Wong PN; Mak SK; Lo KY; Tong GM; Wong AK
Adv Perit Dial; 1998; 14():11-3. PubMed ID: 10649682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
